CHMP positive about Pfizer’s new combination antibiotic

April 19, 2024

In a recent announcement, Pfizer, Inc. shared that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization to EMBLAVEO®, a new antibiotic for treatment of adults with several types of infections, including those caused by resistant aerobic Gram-negative microorganisms.

One of the most common defenses against Gram-negative bacteria is beta-lactam antimicrobials, which inhibit synthesis of the bacterial cell wall to prevent growth. But over time, bacteria have developed clever mechanisms to avoid killing by beta-lactams, including an enzyme that breaks down the antimicrobial before it can alter the cell wall.  

Developed jointly by Abbvie and Pfizer, EMBLAVEO is a combination of an older beta-lactam antimicrobial, aztreonam, and a newer beta-lactamase inhibitor, avibactam. Pfizer and the CHMP hope that this new antibiotic will offer relief to patients suffering from life-threatening Gram-negative bacterial infections that currently do not have much in the way of treatment options.

To review Pfizer’s press release on EMBLAVEO, click the button below:

Analyze with ease and certainty.

Successful surveillance of antimicrobial resistant bacterial infections depends on identification of specific gene families responsible for resistance. The Streck ARM-D® kits are a comprehensive, easy to use, and cost-effective way of detecting these gene families in many Gram-negative bacteria.

Streck ARM-D Kits are for Research Use Only. Not for use in diagnostic procedures.


New antibiotic fights antimicrobial resistant bacteria

Recent work published in Nature has introduced Zosurabalpin, a new antibiotic effective against Carbapenem-resistant Acinetobacter baumannii (CRAB). D…
Read More

2022 HAI Progress Report released by the CDC

When it comes to public health and health care, improvement of patient safety and prevention of adverse events are top priorities for the Centers for …
Read More

CDC expands disease surveillance at major U.S. airports

U.S. airports host more than 1 billion visitors each year, and it’s not just people. New and emerging bacteria, viruses and other microbes travel th…
Read More